anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
BACKGROUND: Pseudo-thrombotic microangiopathy (pseudo- thrombotic microangiopathy (TMA)) is a rare presentation of B12 deficiency. Overlapping features like elevated LDH/total bilirubin with low haemoglobin/haptoglobin/platelets could deceivingly suggest thrombotic thrombocytopenic purpura (TTP) resulting in avoidable procedures/treatments.
CASE PRESENTATION: A 36-year-old female with hypothyroidism initially presented to clinic with fatigue, palpitations, lightheadedness, and dyspnoea over a 3-month duration and was found to have a haemoglobin of 5.7 g/dL. She received two packed red blood cell units in the emergency room and subsequently discharged with outpatient follow-up and empiric oral iron. During her follow-up visit, she was found to have easy bruisability, gum bleeding, and generalized weakness from hemolytic anaemia (mean corpuscular volume (MCV) 90 fL, haptoglobin <8 mg/dL, LDH >4,000 U/L and schistocytosis on CBC) and thrombocytopenia of 52 K/uL. Due to PLASMIC score of 6 and suspicion for TTP, she was transferred to our facility and tr eated with three cycles of plasma exchange and prednisone but were discontinued when ADAMTS13 levels returned normal. While the patient had normal B12 levels, further testing revealed positive intrinsic factor antibodies (IF-Ab) and an elevated MMA level of 1.56 umol/L. Replacement with cobalamin led to normalization of labs and symptoms.
CONCLUSIONS: Timely diagnosis of pseudo-TMA was exceptionally challenging due to several overlapping features with TTP including normal B12 and normal MCV. B12 levels may falsely appear normal in pernicious anemia due to IF-Ab interference with chemiluminescent immunoassay. Schistocytes lower the MCV in automated cell counters. Lower reticulocyte index (<2%), presence of immature/large platelets and teardrop cells, elevated MMA and a higher LDH (>2500) are indicative of B12 deficiency.
PURPOSE: A composition containing salmon fraction for preventing and treating hyperlipidemia and arteriosclerosis is provided to reduce lipid content in feces, serum, and liver tissue. CONSTITUTION: A pharmaceutical composition for preventing and treating hyperlipidemia and arteriosclerosis contains a salmon fraction with anti-obesity and anti-thrombotic effect as an active ingredient. The salmon fraction is obtained by removing intestine, head, tail and bone of whole salmon and extracting with polar solvent. The polar solvent is water, low alcohol of C1-C4 or mixture thereof. A health food for preventing and treating hyperlipidemia and arteriosclerosis contains salmon fraction with anti-obesity and anti-thrombotic effect as an active ingredient. The health food is manufactured in the form of powder, granule, capsule or beverage.
Vitamin D3 placebo (i.e., soybean oil). Mental Health Education: consists of providing a brochure with information about mental health problems and a set of educational mental health videos regarding depression.
Patients with impaired renal function do not generally require a reduction in dose unless the impairment is severe. Renal impairment patients with a glomerular filtration rate of <30 mL/min should not receive the 875 mg/125 mg dose. Patients with a glomerular filtration rate of 10 to 30 mL/min should receive 500 mg/125 mg or 250 mg/125 mg every 12 hours, depending on the severity of the infection. Patients with a glomerular filtration rate less than 10 mL/min should receive 500 mg/125 mg or 250 mg/125 mg every 24 hours, depending on severity of the infection.   
  
Hemodialysis patients should receive 500 mg/125 mg or 250 mg/125 mg every 24 hours, depending on severity of the infection. They should receive an additional dose both during and at the end of dialysis.
The invention relates to a method and manufacturing process of a multiple plant extract composition with effective acne symptom improvement. In the method and manufacturing process of the invention, a plant extract composition is formed by mixing extracts from multiple natural plants that are capable of effectively improving acne symptom and adjusting sebum secretion. The plant extract composition is mainly formed by mixing Forsythia suspensa extract, Smilax glabra extract, Paeonia lactiflora Pall extract, Sophora flavescens Aait extract, Angelica dahurica extract and Scutellaria baicalensis Georgi extract. Accordingly, without adding anti-acne ingredient of chemical and western medicine, the plant extract composition can be formulated to provide efficacies of effectively improving acne symptom, adjusting sebum secretion, soothing and controlling pain, and relieving redness and swelling of the affect part. The invention relates to a method and manufacturing process of a multiple plant extract composition with effective acne symptom improvement. In the method and manufacturing process of the invention, a plant extract composition is formed by mixing extracts from multiple natural plants that are capable of effectively improving acne symptom and adjusting sebum secretion. The plant extract composition is mainly formed by mixing Forsythia suspensa extract, Smilax glabra extract, Paeonia lactiflora Pall extract, Sophora flavescens Aait extract, Angelica dahurica extract and Scutellaria baicalensis Georgi extract. Accordingly, without adding anti-acne ingredient of chemical and western medicine, the plant extract composition can be formulated to provide efficacies of effectively improving acne symptom, adjusting sebum secretion, soothing and controlling pain, and relieving redness and swelling of the affect part.
A modified CAM protocol will be used. Exercises will be performed hourly for 10 repetitions in the form of passive flexion and active extension exercises with an active hold of the fingers in the flexed position for 2-3 seconds.
Multi-parametric magnetic resonance imaging (mpMRI) has emerged as an important tool for identifying clinically significant prostate cancer. We examined if the addition of a 400-variant multi-ancestry polygenic risk score (PRS) to mpMRI has the potential to improve identification. Based on data from 24 617 men from the Mass General Brigham Biobank, we identified 1243 men who underwent mpMRI. Men in the top PRS quartile were more likely to have clinically significant prostate cancer (47.1% vs 28.6% in the bottom PRS quartile, adjusted relative proportion 1.72 [95% CI = 1.35 to 2.19]). Both among men with a positive and a negative mpMRI, men in the top PRS quartile had the highest frequency of clinically significant cancer. In a constructed scenario for selecting men to undergo biopsy, use of the PRS lowered the frequency of missed clinically significant cancers from 9.1% to 5.9%. Our study provides initial support for using the PRS to improve identification of potentially lethal prostate cancer.
OBJECTIVES: Intestinal perforation during acute lymphoblastic leukemia (ALL) treatment in children is rare, but represents a severe complication with possible long-term consequences. In this study, we aim to provide an overview of the epidemiology and clinical characteristics of these patients; analyze surgical pathology findings for possible causes; and determine its impact on patients' therapy, nutritional status, and outcome.
STUDY DESIGN: Historical chart review from January 2000 to October 2020 of children with ALL and intestinal perforation during therapy diagnosed at a single institution. Data collected included patient demographics, anthropometric measurements, ALL characteristics, diagnosis and surgery of intestinal perforation, pathology, adjustments to treatment plan, and outcome.
RESULTS: Of 1840 ALL patients, 13 (0.7%) presented with intestinal perforation during treatment. Perforation occurred during induction phase in 91% of cases. Most patients underwent laparotomy with ostomy creation, and no patient died from the intervention or developed malnutrition. Pathology mainly revealed inflammation at the perforation site. Two samples showed leukemic infiltration and presence of microorganisms. Patients were able to resume ALL therapy in all cases. A total of eight patients (73%) were in first remission at last follow-up, with a median follow-up time of 42 months (interquartile range = 42).
CONCLUSION: Early surgical intervention is a successful treatment approach for intestinal perforation in ALL patients. There is a clear predilection for induction phase in the occurrence of intestinal perforation in ALL patients. No specific cause was identified. Patients can receive bridging chemotherapy during surgical recovery and proceed with their treatment without apparent impact on outcome.
TMZ was administered orally at an initial daily dose of 150 mg/m2 per day for 5 days, every 28 days preoperatively. In patients with a good tolerance during the first cycle, the dose was increased to 200 mg/m2 per day for 5 days, every 28 days.
Here we present the case of a patient who purchased a Hawthorne root (Crataegus mexicana) product, Raiz de Tejocote, for weight loss purposes. She presented with diffuse myalgias, dizziness and a heart rate of 52 beats per minute. At triage and at initial evaluation, the patient denied taking any medications, but on iterative questioning concerning over-the-counter, over-the-internet and herbal medications, she reported taking Hawthorne root tablets in the three days prior to the emergency department (ED) visit for the purpose of weight loss. The product was purchashed through the internet. Her plasma digoxin concentration was 0.4 ng/ml the patient's constellation of symptoms, as well as the detectable plasma digoxin concentration, were consistent with hawthorne root toxicity. Hawthorne root has intrinsic cardiac glycoside activity. In addition, Hawthorne root may cause a range of toxicity. Mild symptoms can include flu-like syndrome with significant myalgias. However, in the more severe exposures the cardiac glycoside effects can result in bradycardia and hemodynamic instability. Symptoms resolved with ED observation. The heart rate normalized. This case reinforces the importance of asking a patient about all medications, including over-the-counter, over-the-internet and herbal medications.
Naproxen oral suspension USP is available as a light orange-colored oral suspension containing 125 mg/5 mL of naproxen for oral administration.   
Naproxen is a propionic acid derivative related to the arylacetic acid group of nonsteroidal anti-inflammatory drugs. The chemical name is (S)-6-methoxy-α-methyl-2-naphthalene acetic acid. The molecular weight is 230.26 Its molecular formula is C 14H 14O 3, and it has the following chemical structure. 

Naproxen, USP is a white to off-white crystalline powder. It is soluble in chloroform, in dehydrated alcohol, in alcohol, sparingly soluble in ether and practically insoluble in ether. It is lipid-soluble, practically insoluble in water.

  


The inactive ingredients in naproxen oral suspension USP include fumaric acid, FD&C yellow 6, microcrystalline cellulose, orange flavor, pineapple fresh flavor, purified water, sodium benzoate, sodium chloride, non-crystallizing sorbitol solution, sucrose and xanthan gum.
Abemaciclib twice daily. 1 cycle of treatment is 21 days in length.
FIELD: medicine. ^ SUBSTANCE: 20 minutes prior to an irradiation procedure in an ultraviolet chamber, an infusion tea of nettle, birch, plantain leaves is introduced orally in a laboratory animal. The infusion tea is prepared of leaves taken in the ratio 1:1:1, by keeping 8 g of the tea in boiling water 200 ml. The infusion tea is introduced at 5 ml/kg of weight daily for 28 days. ^ EFFECT: higher antioxidant activity and decreased degree of radical product and lipid peroxide accumulation, in the absence of side and toxic effects of the plant tea, and applicability in experimental medicine and clinical practice. ^ 4 tbl
OBJECTIVE: Systemic juvenile idiopathic arthritis-associated lung disease (SJIA-LD) is a life-threatening disease complication. Key questions remain regarding clinical course and optimal treatment approaches. The objectives of the study were to detail management strategies after SJIA-LD detection, characterize overall disease courses, and measure long-term outcomes.
METHODS: This was a prospective cohort study. Clinical data were abstracted from the electronic medical record, including current clinical status and changes since diagnosis. Serum biomarkers were determined and correlated with presence of LD.
RESULTS: We enrolled 41 patients with SJIA-LD, 85% with at least one episode of macrophage activation syndrome and 41% with adverse reactions to a biologic. Although 93% of patients were alive at last follow-up (median 2.9 years), 37% progressed to requiring chronic oxygen or other ventilator support, and 65% of patients had abnormal overnight oximetry studies, which changed over time. Eighty-four percent of patients carried the HLA-DRB1*15 haplotype, significantly more than patients without LD. Patients with SJIA-LD also showed markedly elevated serum interleukin-18 (IL-18), variable C-X-C motif chemokine ligand 9 (CXCL9), and significantly elevated matrix metalloproteinase 7. Treatment strategies showed variable use of anti-IL-1/6 biologics and addition of other immunomodulatory treatments and lung-directed therapies. We found a broad range of current clinical status independent of time from diagnosis or continued biologic treatment. Multidomain measures of change showed imaging features were the least likely to improve with time.
CONCLUSION: Patients with SJIA-LD had highly varied courses, with lower mortality than previously reported but frequent hypoxia and requirement for respiratory support. Treatment strategies were highly varied, highlighting an urgent need for focused clinical trials.
A total of 145 (4.6%) subjects 65 years of age and older, while 25 (0.8%) were 75 years of age and older, were enrolled in CIBINQO clinical trials. Clinical trials of CIBINQO did not include sufficient numbers of subjects 65 years of age and older to determine whether they respond differently from younger adult subjects. 

A higher proportion of subjects 65 years of age and older discontinued from clinical trials compared to younger subjects. Among all subjects exposed to CIBINQO, including the long-term extension trial, confirmed ALC <500/mm3 occurred only in subjects 65 years of age and older. A higher proportion of subjects 65 years of age and older had platelet counts <75,000/mm3. The incidence rate of herpes zoster in subjects 65 years of age and older treated with CIBINQO (7.40 per 100 patient-years) was higher than that of subjects 18 to less than 65 years of age (3.44 per 100 patient-years).
Deferasirox is an iron-chelating agent provided as granules for oral use. Deferasirox is designated chemically as 4-[3,5-bis(2-hydroxyphenyl)-1H-1,2,4-triazol-1-yl] benzoic acid and has the following structural formula:

Deferasirox is a white to slightly yellow powder. It has a molecular formula C21H15N3O4 and molecular weight of 373.4 g/mol. It is insoluble in water with a pH of suspension of 4.1.

Deferasirox Oral Granules contain 90 mg, 180 mg, or 360 mg deferasirox. Inactive ingredients include crospovidone, magnesium stearate, microcrystalline cellulose, poloxamer, povidone, silicon dioxide.
Subjects received 1 dose of Nimenrix vaccine at Month 0. Nimenrix vaccine was administered intramuscularly into the deltoid region of the non-dominant arm.
Patients in K41 group received propofol and ketamine in a ratio of 4:1. The 4:1 ketofol mixture was made by combining 20 mL of 1% propofol (10 mg/mL) and 1 mL ketamine (50 mg/ml). Afterward, 29 mL of 0.9% NaCl was added until the volume of mixture was 50 mL. Mixtures were mixed in a 50 mL syringe and were given to patients through a syringe pump (B Braun).
PURPOSE:To collect tetracycline based antibiotics without requiring special reagent and organic solvent in high purity and yield by subjecting a minocycline- containing aqueous solution to one absorption-elution treatment by a nonpolar and high-porous polymer. CONSTITUTION:An aqueous solution containing 7-dimethylamino-6-demethyl-6- deoxytetracycline (hereafter described as minocycline) is absorbed using a nonpolar and high-porous polymer as an absorbent at ambient temperature. Then minocycline is eluted with a polar organic solvent (e.g. methanol) mixable with water. The absorbent is used at 10-100 times amount (cc/g) based on an amount of minocycline in minocycline-containing aqueous solution. The minocycline-containing aqueous solution is preferably absorbed after adjusting pH to 3-9 by adding water thereto.
NEW MATERIAL:3-methoxy-5-(1-hydroxy)heptyl-2(5H)-furanone of the formula. USE:Useful as a bitter stomachic. Giving bitter taste peculiar to medicinal carrot and the tissue-cultured products thereof, thus usable as an active ingredient of medicine compositions having stomachic effect. PREPARATION:The compound of the formula can be obtained by hydrolysis of 3-methoxy-5-(1-0-beta-D-glucopyranosyl)heptyl-2(5H)-furanone contained in Panax ginseng belonging to Araliaceae or its analogous plants or the tissue-cultured products thereof. Specifically, e.g. Panax ginseng is dried and extracted with an organic solvent followed by filtration and then removing the solvent under reduced pressure to effect concentration. Thence, a fractionation is made to obtain a purified bitter glycoside, which is then put to solvolysis in an organic solvent, thus obtaining the compound of the formula.
Lumbar Radiculopathy is a medical condition that occurs when one or more nerve roots in the spinal cord are compressed or damaged, leading to pain, weakness, numbness or tingling sensations in the affected area of the body. This condition can be caused by herniated discs, spinal stenosis, Degenerative disc disease, tumors and infections.This study will be a Randomized Control Trial.The study will be conducted in district Swabi. We will recruit the data from NCS University Rehabilitation Centre Swabi.oswestry disbaility index will be given at the start of study and NPRS to check their pain and disbaility levels.SMWLM will be given to experimental group.Participants will be given Hot pack for 15 minutes, TENS for 10 minutes.The patient receives a set of three repetitions, then three sets of six repetitions, with a 30-second break in between each set of treatments. In this session, a progression was also provided as free SLR overpressure. A total of 6 sessions will be given thrice a week on alternate days for 2 consecutive weeks. The treatment will be given with 5 repetitions of SMWLM and 10 repetitions of spinal mobilization with three sets of transverse glide. Total time duration of the treatment will be around 25-35 minutes§ Pre assessment will be conducted at baseline followed by intervention for 3 days per week for 6 consecutive weeks.Final assessment will be conducted at the end of 6 weeks of intervention
Only one pregnant woman was included in the study at the same time in order to avoid any interruption in the follow-up of the pregnant women. VAS was applied to women in both groups when cervical dilatation was 4 and 9 cm. Approximately two hours after giving birth (to allow mothers to breastfeed their babies and to stabilize the mother's vital signs), the Women's Perception of Supportive Care at Birth Scale and the Perinatal Anxiety Screening Scale were applied.
BACKGROUND: The relationship between thyroid hormone (TH) levels in vivo and osteoarthritis (OA) remains inconclusive. This study aims to investigate the association between TH levels and OA, analyze the effect of triiodothyronine on hypertrophic chondrocyte differentiation and OA progression, and identify potential target genes of triiodothyronine in OA to evaluate its diagnostic value.
METHODS: Two-sample mendelian randomization method was used to probe the causal links between hyperthyroidism and OA. Differentially expressed genes (DEGs) from two RNA-sequencing data in Gene Expression Omnibus (GSE199847 and GSE114007) and enrichment analysis of DEGs (166 commonly upregulated genes and 71 commonly downregulated genes of GSE199847 and GSE114007) was performed to analyze the effect of triiodothyronine (T3) on hypertrophic chondrocyte differentiation and OA. C28/I2 cells treated with T3 and reverse transcription and quantitative real-time polymerase chain reaction were used to validate T3 targeted genes. The diagnostic performance of target genes was assessed by the receiver operating characteristic (ROC) curve and area under the curve (AUC).
RESULTS: There was a positive causal association between hyperthyroidism and OA (IVW result, OR = 1.330, 95% CI 1.136-1.557, P = 0.0004). Weighted median and Weighted mode analysis also demonstrated that hyperthyroidism had a positive causal association with OA (p < 0.05, OR > 1). Bioinformatics analysis indicated T3 can partially induce the emergence of late hypertrophic chondrocyte and promote OA through extracellular matrix organization, blood vessel development, skeletal system development and ossification. Post-T3 treatment, MAFB, C1QTNF1, COL3A1 and ANGPTL2 were significantly elevated in C28/I2 cells. ROC curves in GSE114007 showed that AUC of all above genes were ≥ 0.7.
CONCLUSIONS: This study identified that hyperthyroidism has a positive causal association with OA by MR analysis. T3 induced hypertrophic chondrocytes promote OA progression by upregulating genes such as MAFB, C1QTNF1, COL3A1 and ANGPTL2, which can also serve as OA diagnosis.
PURPOSE: Listening-related fatigue (LRF) is a prominent topic of research interest. The purpose of this study is to investigate the reliability and validity of the Turkish version of the 40-item Vanderbilt Fatigue Scale for Adults (TR-VFS-A-40).
METHOD: This study included 317 adults with no hearing loss and 260 adults with hearing loss in the study group, totaling 577 adults aged 18-75 years. While 31 adults in the study group did not use any hearing technology, there were 96 hearing aid users and 123 cochlear implant (CI) users. A subset of 80 CI users completed the TR-VFS-A-40 a second time, 2 weeks later, to assess test-retest reliability. Intraclass correlation coefficients were used to assess test-retest reliability. Cronbach's alpha was used to evaluate internal consistency. To examine construct validity, a confirmatory factor analysis (CFA) was performed. For concurrent validity analysis, the Checklist Individual Strength (CIS) and TR-VFS-A-40 scores were analyzed using the Spearman correlation test.
RESULTS: Cronbach's alpha values were excellent for the total scale of .987 and the cognitive, emotional, physical, and social subscales (.953, .954, .955, and .946, respectively). Analyses of concurrent validity revealed strong and significant correlations between CIS and TR-VFS-A-40 scores, indicating a good concurrent validity. The CFA determined that the construct validity of the TR-VFS-A-40 was satisfactory.
CONCLUSION: The TR-VFS-A-40 is a valid and reliable measure of LRF.
SUPPLEMENTAL MATERIAL: https://doi.org/10.23641/asha.25457752.
A vitamin concentrate is obtained by treating fish press liquor, after removing the free oil, with a chemical coagulant known to be capable of coagulating readily coagulable proteins, e.g. aluminium sulphate, ferric chloride, tannic acid or preferably sulphuric acid, treating the liquor to remove oil freed by the coagulant and concentrating the resulting liquor.  The coagulated protein material may be separated and the resulting serum treated with an adsorptive agent, e.g. fuller's earth, to adsorb the water-soluble vitamins. Prior to the removal of the coagulated protein the process is carried out at a temperature in excess of 150 DEG  F.  Preferably an acid coagulant is used which will produce a pH between 4 and 5.  A suitable apparatus is described with corresponding drawing.